Find Calcifediol manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

JP

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

83 RELATED EXCIPIENT COMPANIES

142EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Calcidiol, 25-hydroxyvitamin d3, 19356-17-3, 25-hydroxycholecalciferol, Calcifediol anhydrous, Hidroferol
Molecular Formula
C27H44O2
Molecular Weight
400.6  g/mol
InChI Key
JWUBBDSIWDLEOM-DTOXIADCSA-N
FDA UNII
T0WXW8F54E

Calcifediol
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
Calcifediol anhydrous is a Vitamin D3 Analog.
1 2D Structure

Calcifediol

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
2.1.2 InChI
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1
2.1.3 InChI Key
JWUBBDSIWDLEOM-DTOXIADCSA-N
2.1.4 Canonical SMILES
CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
2.1.5 Isomeric SMILES
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
2.2 Other Identifiers
2.2.1 UNII
T0WXW8F54E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 25 Hydroxycholecalciferol

2. 25 Hydroxycholecalciferol Monohydrate

3. 25 Hydroxyvitamin D 3

4. 25 Hydroxyvitamin D3

5. 25-hydroxycholecalciferol

6. 25-hydroxycholecalciferol Monohydrate

7. 25-hydroxyvitamin D 3

8. 25-hydroxyvitamin D3

9. Anhydrous, Calcifediol

10. Calcidiol

11. Calcifediol Anhydrous

12. Calcifediol, (3 Alpha,5z,7e)-isomer

13. Calcifediol, (3 Beta,5e,7e)-isomer

14. Calderol

15. Dedrogyl

16. Hidroferol

17. Monohydrate, 25-hydroxycholecalciferol

2.3.2 Depositor-Supplied Synonyms

1. Calcidiol

2. 25-hydroxyvitamin D3

3. 19356-17-3

4. 25-hydroxycholecalciferol

5. Calcifediol Anhydrous

6. Hidroferol

7. 25-hydroxyvitamin D

8. Calderol

9. Didrogyl

10. Calcifediolum

11. Rayaldee

12. Ro 8-8892

13. 5,6-cis-25-hydroxyvitamin D3

14. Calcifediol [inn]

15. Cholecalciferol, 25-hydroxy-

16. Chebi:17933

17. (3s,5z,7e)-9,10-secocholesta-5,7,10-triene-3,25-diol

18. T0wxw8f54e

19. 3-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexanol

20. Ncgc00161326-04

21. Calcifidiol

22. Delakmin

23. 25-hydroxy Vitamin D3

24. (3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol

25. (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol

26. U-32070e

27. U 32070 E

28. 25-hydroxyvitamin D3 / 25-hydroxycholecalciferol / Calcidiol

29. 25-hydroxycholescalciferol

30. Calcifediolum [inn-latin]

31. Rovimix Hy-d

32. (1s,3z)-3-{2-[(1r,3as,4e,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol

33. (3b,5z,7e)- 9,10-secocholesta-5,7,10(19)-triene-3,25-diol

34. Vitamin D, 25-hydroxy-

35. Hy-d

36. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

37. 36149-00-5

38. 25-(oh)vitamin D3

39. 5,6-trans-25-hydroxycholescalciferol

40. Unii-t0wxw8f54e

41. Ryaldee

42. Bml2-e02

43. (5z,7e)-(3s)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

44. 25(oh)d3

45. Einecs 242-990-9

46. Mfcd00867077

47. U 32070e

48. Calcifediol [mi]

49. (5z,7e)-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol

50. 5,6-trans-9,10-seco-5,7,10(19)-cholestatrien-3beta,25-diol

51. Spectrum5_001931

52. Dsstox_cid_2721

53. 25-hydroxy-cholecalciferol

54. Calcifediol,anhydrous

55. Schembl3296

56. Chembl1040

57. Dsstox_rid_76699

58. Dsstox_gsid_22721

59. Bspbio_001411

60. Calcifediol, Anhydrous

61. (3s,5z,7e)-9,10-seco-5,7,10(19)-cholestatriene-3,25-diol

62. Gtpl6921

63. Dtxsid0022721

64. Chebi:94743

65. Amy2863

66. Bcpp000306

67. Dm100

68. Hms1361g13

69. Hms1791g13

70. Hms1989g13

71. Hms2089l21

72. Hms3402g13

73. 64719-49-9

74. Act06833

75. Zinc4474414

76. Tox21_111987

77. (3s,5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3,25-diol

78. 9,10-secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5z,7e)-

79. Bdbm50521013

80. Calcifediol,anhydrous [vandf]

81. Lmst03020246

82. S1469

83. Akos015965097

84. Bcp9000472

85. Ccg-268657

86. Cs-0800

87. Db00146

88. Idi1_033881

89. Ncgc00161326-01

90. Ac-31367

91. Hy-32351

92. Cas-19356-17-3

93. 25-hydroxycholecalciferol, >=98% (hplc)

94. C01561

95. Ab01275461-01

96. Ab01275461_02

97. 356c173

98. A923587

99. Q139307

100. Sr-05000001468

101. Sr-05000001468-1

102. W-201718

103. 25-hydroxyvitamin D3 Monohydrate, >=99.0% (hplc)

104. 9,10-secocholesta-5,7,10(19)-triene-3b,25-diol

105. Brd-k77175907-001-01-5

106. B91135ec-8937-4d8b-a533-ccd82f33c1b0

107. Calcifediol, European Pharmacopoeia (ep) Reference Standard

108. (5e,7e)-9,10-secocholesta-5,7,10(19)-triene-3beta,25-diol

109. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, 98% (cp)

110. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, 98% (cp)

111. 25-hydroxyvitamin D3 Solution, 50 Mug/ml In Ethanol, 98% (cp)

112. Calcifediol, United States Pharmacopeia (usp) Reference Standard

113. (3s,5z,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-3,25-diol

114. (5z,7e)-9,10-secocholesta-5,7,10(19)-triene-3b,25-diol Monohydrate

115. 9,10-secocholesta-5,7,10(19)-triene-1,25-diol, (3.beta,.5z,7e)-

116. (?r,1r,3as,4e,7ar)-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]octahydro-?,?,?,7a-tetramethyl-1h-indene-1-pentanol

117. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol

118. (s,z)-3-((e)-2-((1r,3as,7ar)-1-((r)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexanol

119. 1h-indene-1-pentanol, Octahydro-4-[(2z)-2-[(5s)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-.alpha.,.alpha.,.epsilon.,7a-tetramethyl-, (.epsilon.r,1r,3as,4e,7ar)-

120. 25-hydroxyvitamin D3 Solution, 100 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material

121. 25-hydroxyvitamin D3 Solution, 5 Mug/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 400.6 g/mol
Molecular Formula C27H44O2
XLogP36.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count2
Rotatable Bond Count6
Exact Mass400.334130642 g/mol
Monoisotopic Mass400.334130642 g/mol
Topological Polar Surface Area40.5 Ų
Heavy Atom Count29
Formal Charge0
Complexity655
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count2
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.


Treatment of secondary hyperparathyroidism (SHPT)


5 Pharmacology and Biochemistry
5.1 Pharmacology

Calcidiol is the precursor of vitamin D3. Vitamin D3 is a steroid hormone that has long been known for its important role in regulating body levels of calcium and phosphorus, in mineralization of bone, and for the assimilation of vitamin A. The classical manifestations of vitamin D deficiency is rickets, which is seen in children and results in bony deformaties including bowed long bones. Deficiency in adults leads to the disease osteomalacia. Both rickets and osteomalacia reflect impaired mineralization of newly synthesized bone matrix, and usually result from a combination of inadequate exposure to sunlight and decreased dietary intake of vitamin D. Common causes of vitamin D deficiency include genetic defects in the vitamin D receptor, severe liver or kidney disease, and insufficient exposure to sunlight. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma.


5.2 MeSH Pharmacological Classification

Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)


Vitamins

Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
CALCIFEDIOL ANHYDROUS
5.3.2 FDA UNII
T0WXW8F54E
5.3.3 Pharmacological Classes
Vitamin D3 Analog [EPC]; Cholecalciferol [CS]
5.4 ATC Code

A - Alimentary tract and metabolism

A11 - Vitamins

A11C - Vitamin a and d, incl. combinations of the two

A11CC - Vitamin d and analogues

A11CC06 - Calcifediol


H - Systemic hormonal preparations, excl. sex hormones and insulins

H05 - Calcium homeostasis

H05B - Anti-parathyroid agents

H05BX - Other anti-parathyroid agents

H05BX05 - Calcifediol


5.5 Absorption, Distribution and Excretion

Absorption

Readily absorbed.


5.6 Metabolism/Metabolites

Calcidiol undergoes hydroxylation in the mitochondria of kidney tissue, and this reaction is activated by the renal 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to produce calcitriol (1,25- dihydroxycholecalciferol), the active form of vitamin D3.


5.7 Biological Half-Life

288 hours


5.8 Mechanism of Action

Calcidiol is transformed in the kidney by 25-hydroxyvitamin D3-1-(alpha)-hydroxylase to calcitriol, the active form of vitamin D3. Calcitriol binds to intracellular receptors that then function as transcription factors to modulate gene expression. Like the receptors for other steroid hormones and thyroid hormones, the vitamin D receptor has hormone-binding and DNA-binding domains. The vitamin D receptor forms a complex with another intracellular receptor, the retinoid-X receptor, and that heterodimer is what binds to DNA. In most cases studied, the effect is to activate transcription, but situations are also known in which vitamin D suppresses transcription. Calcitriol increases the serum calcium concentrations by: increasing GI absorption of phosphorus and calcium, increasing osteoclastic resorption, and increasing distal renal tubular reabsorption of calcium. Calcitriol appears to promote intestinal absorption of calcium through binding to the vitamin D receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.


USDMF

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed

02

Carbogen Amcis Bv

Netherlands

USDMF

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

02

Carbogen Amcis Bv

Netherlands
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-07-28

Pay. Date : 2016-07-08

DMF Number : 21963

Submission : 2008-09-05

Status : Active

Type : II

blank

03

Pharma, Lab & Chemical Expo
Not Confirmed

04

Solvay Duphar Bv

Germany

USDMF

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

04

Pharma, Lab & Chemical Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 12386

Submission : 1997-02-27

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Certificate Number : CEP 1998-059 - Rev 09

Status : Valid

Issue Date : 2024-12-02

Type : Chemical and TSE

Substance Number : 1295

blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Certificate Number : R0-CEP 2022-335 - Rev 00

Status : Valid

Issue Date : 2022-11-29

Type : Chemical

Substance Number : 1295

blank

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Certificate Number : R0-CEP 2015-359 - Rev 01

Status : Withdrawn by Holder

Issue Date : 2022-08-09

Type : Chemical

Substance Number : 1295

blank

DSM Nutritional Products Ltd. Basel...

Contact Supplier
Flag Gabon
Virtual Booth Virtual Booth
Digital Content Digital Content
R1-CEP 1999-101 - Rev 02
Withdrawn by Holder
Chemical
2012-06-07
2018-12-19
1295
blank

05

DSM Nutritional Products Ltd. Basel...

Gabon
BIO Partnering at JPM
Not Confirmed
arrow

DSM Nutritional Products Ltd. Basel...

Gabon
arrow
BIO Partnering at JPM
Not Confirmed

Certificate Number : R1-CEP 1999-101 - Rev 02

Status : Withdrawn by Holder

Issue Date : 2012-06-07

Type : Chemical

Substance Number : 1295

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

CARBOGEN AMCIS B.V.

Switzerland
BIO Partnering at JPM
Not Confirmed
arrow

CARBOGEN AMCIS B.V.

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

CALCIFEDIOL ANHYDROUS

NDC Package Code : 45408-002

Start Marketing Date : 2012-08-31

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

CALCIFEDIOL

NDC Package Code : 66499-0065

Start Marketing Date : 2019-09-06

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...

We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to market while improving the lives of their patients across the world. Our objective is to help our customers create a better world as the partner of choice to develop and manufacture complex and challenging substances, highly potent active ingredients, and breaking new ground with innovative vitamin, healthcare, and industrial products.
blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : DISHMAN Netherlands is located in Veenendaal in the middle of the Netherlands. We are active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol a...

DISHMAN Netherlands is located in Veenendaal in the middle of the Netherlands. We are active in the marketing/sales and manufacture of Vitamin D analogues, Vitamin D, Cholesterol and lanolin related products for key markets as pharmaceutical, cosmetic, feed, food, shrimp farming and industry applications. Our Vitamin D analogue products include: Alfacalcidol, Calcifediol, Calcitriol, & Dihydrotachysterol-2. These analogues are used in pharmaceutical products to combat Osteoporosis, rickets etc. Vitamin D2 and D3 are manufactured for use in the food, feed and pharmaceutical industries. Cholesterol is used in diverse applications such as drug d
blank

03

DongWha Pharm

South Korea
BIO Partnering at JPM
Not Confirmed
arrow

DongWha Pharm

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : DongWha is the company that "serves customers by making good medicines and is managed with the rewards generated by benefits of good medicines." Under its corporate philosophy that...

DongWha is the company that "serves customers by making good medicines and is managed with the rewards generated by benefits of good medicines." Under its corporate philosophy that places the foremost priority on health and safety of its customers, it continues to work toward happiness of customers. Based on respect for the shared value that "we work diligently in our youth and live fruitful lives in old age." it serves every customer faithfully by fostering ownership and faith among its members.
blank

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspecti...

Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspections from regulatory authorities around the world, Formosa now provides CDMO service extending from APIs and ADCs (Antibody Drug Conjugates) to cytotoxic and non-cytotoxic injectables of aseptic liquid filling and lyophilization. Formosa Laboratories is able to offer full-service GMP manufacturing for drug substance, ADCs and drug product with its API and injectable facilities that accommodates small molecules, biologics and ADCs etc.
blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...

Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediates, and fine chemicals for worldwide markets. With decades of development, now we grow to a leading and outstanding company. We are not just a trading company, but a comprehensive solutions supplier. With our sound knowledge of pharmaceutical business, our advantage is to integrate resources and adapt to all different demands of markets. We are a young but dynamic and energetic company with high efficient and high flexible decision making system.
blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...

Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical intermediates and new drugs. The company is mainly engaged in customized synthesis of complex small molecule frameworks and pharmaceutical intermediates, and independent R&D of innovative new drugs; and provides services of production technology improvement and consigned new drug development for pharmaceutical enterprises. Haoyuan Chemexpress is committed to researching and developing APIs and pharmaceutical intermediates with high synthesis technology barriers and difficulties and high added value, and also focuses on the synthesis of chiral compounds.
blank

07

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Calcifediol

About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...

Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Center & 1 Mfg. Site which has been certified by US FDA, JPMDA & EMA, supported by >550 highly trained professionals across departments & >200 scientists to bring high quality products to customers. More than 130 products/projects have been successfully developed since founded. Process Innovation, R&D Efficiency & Cost Effectiveness are Ausun's key competencies. Create Chemistry and to be the 1st Class Worldwide Pharmaceutical Corporation is our goal.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.


Lead Product(s): Calcifediol

Therapeutic Area: Endocrinology Brand Name: Rayaldee

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Vifor Fresenius Medical Care Renal Pharma

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2022

blank

01

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Lead Product(s) : Calcifediol

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Vifor Fresenius Medical Care Renal Pharma

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Brand Name : Rayaldee

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 03, 2022

blank

Details:

RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a 2-week follow-up.


Lead Product(s): Calcifediol

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2021

blank

02

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : RAYALDEE is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The REsCue trial randomized symptomatic COVID-19 outpatients in a 1:1 ratio to 4 weeks of treatment with RAYALDEE or placebo and a...

Brand Name : Rayaldee

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 30, 2021

blank

Details:

Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact iPTH.


Lead Product(s): Calcifediol

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2021

blank

03

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Rayaldee is an extended-release oral formulation of calcifediol, a prohormone of calcitriol, the active form of vitamin D3. The product is the first and only medicine approved by the US FDA for raising serum total 25D and lowering blood levels of intact ...

Brand Name : Rayaldee

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 30, 2021

blank

Details:

OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.


Lead Product(s): Calcifediol

Therapeutic Area: Endocrinology Brand Name: Rayaldee

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: CSL Vifor

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination May 24, 2021

blank

04

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : OPKO Health announced a transfer of the licensed rights to RAYALDEE in Japan from Japan Tobacco to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE® in Japan to VFMCRP.

Brand Name : Rayaldee

Molecule Type : Small molecule

Upfront Cash : Undisclosed

May 24, 2021

blank

Details:

The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).


Lead Product(s): Calcifediol

Therapeutic Area: Infections and Infectious Diseases Brand Name: Rayaldee

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2020

blank

05

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : The randomized, double-blind placebo-controlled study will evaluate the safety and efficacy of RAYALDEE (calcifediol) extended-release capsules to treat symptomatic patients infected with SARS-CoV-2 (REsCue).

Brand Name : Rayaldee

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 15, 2020

blank

Details:

The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.


Lead Product(s): Calcifediol

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

blank

06

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

OPKO Health

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : The REsCue trial will have 4 weeks of treatment with RAYALDEE or placebo and 2 weeks of follow-up. The objective is to raise and maintain serum total 25-hydroxyvitamin D (25D) within the range of 50-100 ng/mL in order to mitigate COVID-19 severity.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 01, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Pharmatech Expo 2025
Not Confirmed
arrow
arrow
Pharmatech Expo 2025
Not Confirmed

Calcifediol

Brand Name : DIDROGYL

Dosage Form : Oral Drops Solution

Dosage Strength : 1.5 mg/10 ml

Packaging : 10 ML 0.15 MG/ML - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

02

Pharmatech Expo 2025
Not Confirmed
arrow
arrow
Pharmatech Expo 2025
Not Confirmed

Calcifediolum

Brand Name : Rayaldee

Dosage Form : Caps

Dosage Strength : 30mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

03

Pharmatech Expo 2025
Not Confirmed
arrow
arrow
Pharmatech Expo 2025
Not Confirmed

Calcifediol

Brand Name : VIDENKA

Dosage Form : Oral Drops Solution

Dosage Strength : 0.15 mg/ml

Packaging : 10 ML 0.15 MG/ML - ORAL USE

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

04

BRUNO FARMACEUTICI SpA

Country
Pharmatech Expo 2025
Not Confirmed
arrow

BRUNO FARMACEUTICI SpA

Country
arrow
Pharmatech Expo 2025
Not Confirmed

Calcifediol

Brand Name : Didrogyl

Dosage Form : Calcifediolo 1,5Mg/10Ml Oral Use

Dosage Strength : os gtt soluz 1.5 mg 10 ml

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Controlled & Modified Release

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Empty Capsules

read-more
read-more

Vegetarian Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

API Stability Enhancers

read-more
read-more

Direct Compression

read-more
read-more

Emulsifying Agents

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Soft Gelatin

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 36,135,698

Year : 2022

Prescribers : 4175

Prescriptions : 26091

blank

02

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 39,639,508

Year : 2021

Prescribers : 4919

Prescriptions : 28393

blank

03

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 61,315,676

Year : 2020

Prescribers : 6792

Prescriptions : 44119

blank

04

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 45,863,706

Year : 2019

Prescribers : 6659

Prescriptions : 34106

blank

05

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 20,943,011

Year : 2018

Prescribers : 3736

Prescriptions : 17194

blank

06

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 5,122,073

Year : 2017

Prescribers : 1333

Prescriptions : 4255

blank

07

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 19,456

Year : 2016

Prescribers : 16

Prescriptions : 16

blank

08

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company :

Calcifediol

Drug Cost (USD) : 0

Year : 2015

Prescribers :

Prescriptions : 0

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 9498486

Drug Substance Claim :

Drug Product Claim :

Application Number : 208010

Patent Use Code : U-3814

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-25

blank

02

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 9925147

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208010

Patent Use Code : U-2256

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-25

blank

03

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 11154509

Drug Substance Claim :

Drug Product Claim :

Application Number : 208010

Patent Use Code : U-3815

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-25

blank

04

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 8426391

Drug Substance Claim :

Drug Product Claim :

Application Number : 208010

Patent Use Code : U-1872

Delist Requested :

Patent Use Description : USE OF SUSTAINED RELEA...

Patent Expiration Date : 2028-08-27

blank

05

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 9861644

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208010

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-14

blank

06

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 9925147

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208010

Patent Use Code : U-2257

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-25

blank

07

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 8778373

Drug Substance Claim :

Drug Product Claim :

Application Number : 208010

Patent Use Code : U-1873

Delist Requested :

Patent Use Description : ADMINISTRATION OF 25-H...

Patent Expiration Date : 2028-04-25

blank

08

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 8361488

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208010

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-07-19

blank

09

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 9408858

Drug Substance Claim :

Drug Product Claim :

Application Number : 208010

Patent Use Code : U-1888

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2028-04-25

blank

10

arrow
Pharmatech Expo 2025
Not Confirmed

EIRGEN

United Kingdom
arrow
Pharmatech Expo 2025
Not Confirmed

CALCIFEDIOL

US Patent Number : 10300078

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208010

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-03-14

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

EDQM

read-more
read-more

01

EDQM, Council of Europe

Calcifediol - reference spectrum

arrow
Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Calcifediol - reference spectrum

CAS Number : n/a

Quantity Per Vial : n/a

Sale Unit : 1

Order Code : C0166001

Batch No : 1

Price (€) : 79

Storage :

blank

02

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Calcifediol

CAS Number : 63283-36-3

Quantity Per Vial : 5 mg

Sale Unit : 1

Order Code : C0166000

Batch No : 6

Price (€) : 150

Storage : -20°C ± 5°C

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USP

read-more
read-more

01

USP

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

USP

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

Calcifediol (75 mg)

CAS Number : 63283-36-3

Quantity Per Vial :

Price ($) : 715

Catalog Number : 1086108

Current Lot : R03160

Previous Lot : G2K349 (30-NOV-2016)

NDC Code :

blank

ABOUT THIS PAGE

Calcifediol Manufacturers

A Calcifediol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcifediol, including repackagers and relabelers. The FDA regulates Calcifediol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcifediol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Calcifediol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Calcifediol Suppliers

A Calcifediol supplier is an individual or a company that provides Calcifediol active pharmaceutical ingredient (API) or Calcifediol finished formulations upon request. The Calcifediol suppliers may include Calcifediol API manufacturers, exporters, distributors and traders.

click here to find a list of Calcifediol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Calcifediol USDMF

A Calcifediol DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcifediol active pharmaceutical ingredient (API) in detail. Different forms of Calcifediol DMFs exist exist since differing nations have different regulations, such as Calcifediol USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Calcifediol DMF submitted to regulatory agencies in the US is known as a USDMF. Calcifediol USDMF includes data on Calcifediol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcifediol USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Calcifediol suppliers with USDMF on PharmaCompass.

Calcifediol CEP

A Calcifediol CEP of the European Pharmacopoeia monograph is often referred to as a Calcifediol Certificate of Suitability (COS). The purpose of a Calcifediol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcifediol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcifediol to their clients by showing that a Calcifediol CEP has been issued for it. The manufacturer submits a Calcifediol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcifediol CEP holder for the record. Additionally, the data presented in the Calcifediol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcifediol DMF.

A Calcifediol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcifediol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Calcifediol suppliers with CEP (COS) on PharmaCompass.

Calcifediol NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Calcifediol as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Calcifediol API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Calcifediol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Calcifediol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Calcifediol NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Calcifediol suppliers with NDC on PharmaCompass.

Calcifediol GMP

Calcifediol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Calcifediol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcifediol GMP manufacturer or Calcifediol GMP API supplier for your needs.

Calcifediol CoA

A Calcifediol CoA (Certificate of Analysis) is a formal document that attests to Calcifediol's compliance with Calcifediol specifications and serves as a tool for batch-level quality control.

Calcifediol CoA mostly includes findings from lab analyses of a specific batch. For each Calcifediol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Calcifediol may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcifediol EP), Calcifediol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcifediol USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty